Multidrug-Resistant Gram-Negative Bacteria in Burn Patients

Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0068822. doi: 10.1128/aac.00688-22. Epub 2022 Sep 6.

Abstract

Patients with burn injuries are at high risk for infectious complications, and infections are the most common cause of death after the first 72 h of hospitalization. Hospital-acquired infections caused by multidrug resistant (MDR) Gram-negative bacteria (GNB) in this population are concerning. Here, we evaluated carriage with MDR GNB in patients in a large tertiary-care burn intensive care unit. Twenty-nine patients in the burn unit were screened for intestinal carriage. Samples were cultured on selective media. Median time from admission to the burn unit to first sample collection was 9 days (IQR 5 - 17 days). In 21 (72%) patients, MDR GNB were recovered; the most common bacterial species isolated was Pseudomonas aeruginosa, which was found in 11/29 (38%) of patients. Two of these patients later developed bloodstream infections with P. aeruginosa. Transmission of KPC-31-producing ST22 Citrobacter freundii was detected. Samples from two patients grew genetically similar C. freundii isolates that were resistant to ceftazidime-avibactam. On analysis of whole-genome sequencing, blaKPC-31 was part of a Tn4401b transposon that was present on two different plasmids in each C. freundii isolate. Plasmid curing experiments showed that removal of both copies of blaKPC-31 was required to restore susceptibility to ceftazidime-avibactam. In summary, MDR GNB colonization is common in burn patients and patient-to-patient transmission of highly resistant GNB occurs. These results emphasize the ongoing need for infection prevention and antimicrobial stewardship efforts in this highly vulnerable population.

Keywords: Citrobacter; Pseudomonas aeruginosa; burn; carbapenemase; ceftazidime-avibactam; hospital infections; plasmid-mediated resistance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azabicyclo Compounds / therapeutic use
  • Ceftazidime / therapeutic use
  • Drug Resistance, Multiple, Bacterial / genetics
  • Gram-Negative Bacteria*
  • Gram-Negative Bacterial Infections* / microbiology
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas aeruginosa / genetics
  • beta-Lactamases / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Ceftazidime
  • beta-Lactamases